$1.61
Down 4.73% · live quote Sep 3, 2026
Market cap
$1.20B
Market cap $1.20B
Adjust assumptions
Adjust the usable peer mix to see how each valuation multiple moves the blended fair value.
Peer-implied fair value
$5.83
Blended value per share under the current mix.
Current price
$1.61
Sep 03, 2026
Peer gap
+261.9%
Peers imply 261.9% upside
Weighting mixer
Value contribution
5 peers →Price / Sales
$4.35B
Price / Sales
$4.35B
Equal-weight baseline
Premium 0.0%The simple average of every usable peer method, before your weighting adjustments.
Baseline equity value
$4.35B
Baseline / share
$5.83
Relative valuation prices this company against what the market already pays for its peers. For a cash-flow view that does not inherit peer sentiment, open the intrinsic model.
Spreadsheet data
Audit the saved peer set and the method inputs behind the blended fair value.
The saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market cap | Enterprise value | Revenue |
|---|
| EBITDA |
|---|
| Net income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
AMRN AMARIN CORP PLC\UK FY ended Dec 31, 2025 | $13.71 | $5.76B | $5.61B | $213.65M | -$32.92M | -$38.80M | -152.33x | 26.95x | — |
SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $22.99 | $2.43B | $3.00B | $2.20B | -$686.34M | -$713.41M | -3.22x | 1.10x | — |
AMPH Amphastar Pharmaceuticals, Inc. FY ended Feb 20, 2026 | $23.84 | $1.01B | $1.32B | $719.89M | $207.48M | $98.09M | 11.74x | 1.41x | 5.49x |
SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.97 | $2.56B | $2.08B | $718.95M | $60.82M | -$38.55M | -64.66x | 3.55x | 29.41x |
HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $41.86 | $2.44B | $2.05B | $868.45M | $262.93M | $158.69M | 15.45x | 2.81x | 7.37x |
AMRN
AMARIN CORP PLC\UK
$13.71
$5.76B
$5.61B
$213.65M
-$32.92M
-152.33x
26.95x
—
Cap $5.76BEV $5.61BRev $213.65MEBITDA -$32.92MP/E -152.33xP/S 26.95xEV/EBITDA —
SRPT
Sarepta Therapeutics, Inc.
$22.99
$2.43B
$3.00B
$2.20B
-$686.34M
-3.22x
1.10x
—
Cap $2.43BEV $3.00BRev $2.20BEBITDA -$686.34MP/E -3.22xP/S 1.10xEV/EBITDA —
AMPH
Amphastar Pharmaceuticals, Inc.
$23.84
$1.01B
$1.32B
$719.89M
$207.48M
11.74x
1.41x
5.49x
Cap $1.01BEV $1.32BRev $719.89MEBITDA $207.48MP/E 11.74xP/S 1.41xEV/EBITDA 5.49x
SUPN
SUPERNUS PHARMACEUTICALS, INC.
$43.97
$2.56B
$2.08B
$718.95M
$60.82M
-64.66x
3.55x
29.41x
Cap $2.56BEV $2.08BRev $718.95MEBITDA $60.82MP/E -64.66xP/S 3.55xEV/EBITDA 29.41x
HRMY
Harmony Biosciences Holdings, Inc.
$41.86
$2.44B
$2.05B
$868.45M
$262.93M
15.45x
2.81x
7.37x
Cap $2.44BEV $2.05BRev $868.45MEBITDA $262.93MP/E 15.45xP/S 2.81xEV/EBITDA 7.37x
Which peer averages feed the weighted fair value, and which methods are excluded.
| Method | Type | Avg. multiple | Coverage | Implied equity value | Fair value / share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 17.57x | 3/5 | -$2.11B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 7.17x | 5/5 | $4.35B | $5.83 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -38.61x | 5/5 | $8.71B | $11.67 | Peer averages are not economically meaningful for this method. |
EV / EBITDA
EV · Enterprise Multiple
Avg. multiple
17.57x
Coverage
3/5
Implied equity value
-$2.11B
Fair value / share
—
Target fundamentals do not produce a usable positive equity value.
Price / Sales
PS · Equity Multiple
Avg. multiple
7.17x
Coverage
5/5
Implied equity value
$4.35B
Fair value / share
$5.83
Included in the active peer mix.
Price / Earnings
PE · Equity Multiple
Avg. multiple
-38.61x
Coverage
5/5
Implied equity value
$8.71B
Fair value / share
$11.67
Peer averages are not economically meaningful for this method.
